Estrogen replacement therapy and risk of epithelial ovarian cancer
Estrogen replacement therapy and risk of epithelial ovarian cancer
复制标题
DOI：
10.1006/gyno.1996.0315
复制
发表时间：
1996-11-01
影响因子：
4.7
通讯作者：
Risch, HA
中科院分区：
文献类型：
--
作者：
Risch, HA
雌激素替代疗法（ERT），在绝经期妇女中常用，一直与卵巢癌的风险不一致。部分不一致可能是由于根据肿瘤组织学的风险差异。因此，我们在组织学组内比较了367例浸润性上皮性卵巢癌和564例对照组的ERT治疗史。在调整年龄、产次、口服避孕药使用和其他因素的多变量logistic回归分析中，非粘液性卵巢癌的相对几率在使用ERT的每一年增加5.1%[即，校正比值比，1.051; 95%置信区间（CI），1.01-1.09，作为每年使用的倍增因子]。特别是，与从未使用ERT的女性相比，使用ERT总计5年或更长时间的女性患浆液性癌的相对几率为2.03（95% CI，1.04-3.97），患类浆液性癌的相对几率为2.81（95% CI，1.15-6.89）。粘液性肿瘤与用药无关。ERT的使用可能会导致非粘液性卵巢癌的发生，在其他研究中需要对这种相关性进行额外的组织学特异性分析。(C)出版社：Academic Press，Inc.
Estrogen replacement therapy (ERT), in common use among menopausal women, has been inconsistently related to risk of ovarian cancer. Part of the inconsistency may be due to differences in risk according to tumor histology. We therefore compared, within histologic groups, 367 cases of invasive epithelial ovarian cancer to 564 population controls on history of ERT practices. In multivariate logistic regression analyses adjusted for age, parity, oral-contraceptive usage, and other factors, the relative odds of nonmucinous ovarian cancer increased by 5.1% for each year of ERT use [i.e., adjusted odds ratio, 1.051; 95% confidence interval (CI), 1.01-1.09, as a multiplicative factor for each year of use]. In particular, compared to never use, women who employed ERT for a total of 5 years or longer had a relative odds of 2.03 (95% CI, 1.04-3.97) of having a serous carcinoma and 2.81 (95% CI, 1.15-6.89) of having an endometrioid carcinoma. Mucinous tumors were not associated with use. ERT usage may contribute to the development of nonmucinous types of ovarian cancer, and additional histology-specific analysis of this association in other studies is warranted. (C) 1996 Academic Press, Inc.